A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

An Open-Label Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Inclusion Criteria:

• Relapsed or Refractory Multiple Myeloma
• ≥ 18 years old
• Able to provide consent for participation
• ECOG status 0-2

Lab values:

• ANC ≥ 1,000/µL
• WBC count ≥ 2.0/µL
• Hemoglobin ≥ 8.0 g/dL
• Platelet count ≥ 50,000/µL
• AST and ALT ≤ 2 x ULN
• Total Bilirubin ≤ 2 x ULN
• Creatinine ≤ 2.0 mg/dL

and

• Not pregnant or lactating